NewAmsterdam Pharma Company N.V. (NAMS) reported Q1 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NAMS Hot Sheet
Join SI Premium – FREE
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) reported Q1 Revenue for the quarter came in at $3.04 million versus the consensus estimate of $1.18 million.
For earnings history and earnings-related data on NewAmsterdam Pharma Company N.V. (NAMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on NewAmsterdam Pharma Co NV (NAMS): 'continue to think the setup here is very compelling and significantly upside-biased'
- Intel shares fall as competitor reports record results
- Sweetgreen (SG) call put ratio 16.4 calls to 1 put into quarter results
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
